Peak Inspiratory Flow in COPD Patients Treated with Pressurized Metered-Dose Inhalers and Spacers: Implications for Inhaler Selection. A Multicenter Cross-Sectional Study Authors: Lara Bravo Quiroga, Jose Miguel González-Moro Rodríguez, Francisco Javier Álvarez-Gutiérrez, Krasimira Baynova, Mariam de la Poza Abad, Jose Luis Izquierdo-Alonso Published: 2026 ABSTRACT AbstractBackgroundSpacer devices are frequently prescribed with pressurized metered-dose inhalers (pMDIs) in patients with COPD for a variety of clinical and practical reasons, including concerns about inspiratory capacity, inhaler technique, and hand–breath coordination. However, inspiratory flow is rarely measured objectively.PurposeTo determine whether COPD patients treated with pMDIs and spacers can generate adequate peak inspiratory flow (PIF) for dry powder inhaler (DPI) use, to evaluate the impact of incomplete exhalation, and to examine patient perceptions of spacer use.Patients and MethodsThis multicenter, cross-sectional study included 273 clinically stable COPD patients treated with pMDIs and spacers across 70 Spanish centers. PIF was measured with the In-Check Dial at medium-low (R2) and medium-high (R4) resistance under both standard and suboptimal conditions. Patient knowledge, satisfaction, and perceived barriers were evaluated using structured study questionnaires.ResultsOverall, 96.0% of patients achieved a PIF ≥30 L/min at R4, whereas 61.9% reached ≥60 L/min. Incomplete exhalation had only a limited effect on inspiratory performance, with 94.1% of patients maintaining a PIF ≥30 L/min at R4. Lower PIF was associated with greater dyspnea and more severe airflow limitation in bivariate analyses. Spacer prescription was seldom based on objective PIF assessment. Most patients reported practical limitations associated with spacer use and expressed a preference for simpler inhaler devices.ConclusionMost COPD patients treated with pMDIs and spacers appear to have sufficient inspiratory capacity to use medium- to high-resistance DPIs. Routine objective assessment of PIF may help optimize individualized inhaler selection and identify patients who could benefit from alternative inhaler devices.Keywords: COPD, dry powder inhalers, peak inspiratory flow, pMDI+spacer, patient satisfaction Introduction In chronic obstructive pulmonary disease (COPD), selecting the appropriate inhaler device is as important as choosing the active medication to achieve optimal therapeutic effectiveness. Despite decades of innovation in inhaled drug delivery systems, inhaler selection in routine clinical practice is still frequently based on empirical criteria rather than objective physiological assessment.1 One factor that may influence the prescription of pressurized metered-dose inhalers with spacers is the perception that some patients have insufficient inspiratory capacity to use dry powder inhalers. Nevertheless, inhaler selection is multifactorial and may also be influenced by inhaler technique, hand–breath coordination, patient characteristics, and clinician preference. In many cases, the decision is driven by the perception of technical difficulties—such as poor hand–breath coordination—rather than by direct measurement of inspiratory capacity and is rarely supported by objective functional assessment.2,3 Peak inspiratory flow (PIF) is a simple, reproducible, and clinically relevant measure of a patient’s ability to generate sufficient inspiratory flow for dry powder inhalers with different internal resistances. Measurement with tools such as the In-Check Dial provides a practical estimate of inspiratory flow against specific resistance settings.4 Despite its clinical relevance, routine PIF assessment remains uncommon in daily practice, even though suboptimal PIF has been associated with worse clinical outcomes in COPD.5,6 Previous studies have reported considerable variability in the proportion of patients with suboptimal PIF, ranging from 20% to 45% in stable outpatient populations.6,7 More recently, within the broader USE-DPI research program, we evaluated inspiratory flow capability in asthma patients treated with pMDIs and valved holding chambers, showing that most were able to achieve sufficient inspiratory flow for medium- to high-resistance DPIs.8 Higher rates of suboptimal PIF have also been reported in hospitalized patients with COPD.9 Together, these findings indicate that inspiratory capacity is highly variable and support the need for an individualized approach to inhaler selection. This raises an important clinical question: do COPD patients currently treated with pMDI+S truly have an inspiratory limitation that justifies this choice, or is there a degree of prescription inertia leading to the use of more complex devices without an objective physiological basis? A mismatch between patients’ functional capacity and the selected inhaler device could have important implications for both treatment effectiveness and treatment burden. COPD is characterized by persistent airflow limitation, hyperinflation, and inspiratory muscle dysfunction, all of which may substantially affect inspiratory performance and inhaler suitability. To address this question, we objectively assessed PIF in a cohort of COPD patients treated with pMDI+S in routine clinical practice. We also evaluated the impact of one of the most common inhalation errors—insufficient exhalation before inhalation—and explored clinical factors associated with reduced inspiratory capacity, together with patients’ perceptions and experiences with their current inhaler device. Methods Study Design and Population This was a multicenter, cross-sectional, observational study conducted at 70 Spanish centers, including both pulmonology and primary care settings. Patients were consecutively recruited over a six-month period. The multicenter design was intended to reflect routine clinical practice, while standardized study procedures were implemented to minimize inter-investigator variability. A total of 273 patients with a confirmed diagnosis of COPD according to GOLD criteria1 were consecutively recruited. All patients were clinically stable (no exacerbations within the previous 4 weeks) and were receiving maintenance treatment with pMDI+S. Inclusion criteria were age≥40 years, spirometry-confirmed COPD, and current use of a pMDI with a spacer. Patients with severe comorbidities or cognitive impairment that could interfere with correct performance of the study manoeuvres were excluded. When available, the reasons for spacer prescription were documented by the investigators during the study visit according to the treating physician’s clinical judgment. No formal sample size calculation was performed because the USE-DPI study was originally designed as a multicenter, cross-sectional observational study including patients with asthma and COPD. The planned sample size of approximately 600 patients was based on study feasibility, considering the participation of approximately 70 investigators, each expected to recruit around 10 consecutive eligible patients, as specified in the study protocol. During the study visit, patients completed three structured questionnaires assessing knowledge of inhaler devices and spacer therapy, satisfaction with spacer use, and perceived barriers to inhaler use. The study materials are provided as Supplementary Questionnaires S1–S3. Measurement of Inspiratory Flow Peak inspiratory flow (PIF) was measured using the In-Check Dial device (Clement Clarke International) at two resistance settings: medium-low (R2) and medium-high (R4), simulating the internal resistance of different commercially available DPIs.4,10 After standardized instruction, patients were asked to perform a rapid, deep inhalation from residual volume to total lung capacity (standard manoeuvre), and the best of two attempts was recorded. Each manoeuvre was supervised by the investigator to ensure correct execution and repeated if an evident technical error occurred. As an exploratory assessment, PIF measurement was repeated after incomplete exhalation (from functional residual capacity), simulating one of the most common inhalation technique errors encountered in routine clinical practice.11,12 To ensure consistency across participating centers, all healthcare professionals received standardized training before patient recruitment. Variables and Statistical Analysis The primary outcome was the proportion of patients achieving a PIF ≥30 L/min, a threshold considered sufficient to activate most medium- to high-resistance DPIs.10 Secondary outcomes included the proportion of patients achieving PIF ≥60 L/min and the effect of incomplete exhalation. Patient knowledge of their treatment, satisfaction with spacer use, and perceived barriers to its use were assessed using three structured study-specific questionnaires (Supplementary Questionnaires S1–S3). The satisfaction questionnaire comprised 10 items scored on a five-point scale ranging from 5 (highest satisfaction) to 1 (no satisfaction). One item specifically assessed the patient’s overall satisfaction with spacer use, and the results reported for overall satisfaction are based exclusively on this item. Continuous variables are presented as mean ± standard deviation and categorical variables as frequencies and percentages. A multivariable logistic regression analysis was initially planned for the ≥30 L/min threshold. However, because 96.0% of patients achieved this outcome at R4, the number of events was insufficient for reliable multivariable model estimation. Consequently, the planned multivariable analysis was not performed, and associations between clinical factors and PIF thresholds were explored using bivariate comparisons. Statistical analyses were performed using Stata (version 17). Ethical Considerations The study was approved by the Research Ethics Committee (CEIm) of Hospital Universitario General de Guadalajara–Universidad de Alcalá (Ref. CEIm: 2024.02.EO) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. All participants provided written informed consent. Results A total of 273 patients were included (mean age 70.5 ± 10.4 years; 33.3% female). Overall, 63.0% were former smokers and 29.7% were current smokers. Most patients had moderate airflow limitation, with 55.6% presenting an FEV1 of 50–79% predicted, 26.8% an FEV1 of 30–49% predicted, and only 4.3% very severe airflow obstruction (FEV1 <30% predicted). Severe dyspnea (mMRC grade 3–4) was present in 21.9% of patients. Baseline characteristics are summarized in Table 1. Table 1Clinical and Functional Characteristics of the Study Population (N = 273)VariableValueAge, years, mean ± SD70.5 ± 10.4Age at diagnosis, years, mean ± SD58.7 ± 11.0Female sex, n (%)91 (33.3)Smoking status, n (%)Never smoker20 (7.3)Former smoker172 (63.0)Current smoker81 (29.7)Comorbidities, n (%)Any comorbidity220 (80.6)Cardiovascular149 (54.6)Metabolic110 (40.3)Oncologic32 (11.7)Airflow limitation (GOLD spirometric grade), n (%)GOLD 1 FEV1 ≥80%34 (13.2)GOLD 2 FEV1 50–79%143 (55.6)GOLD 3 FEV1 30–49%69 (26.8)GOLD 4 FEV1 <30%11 (4.3)Dyspnea (mMRC scale), n (%)09 (3.4)182 (30.9)2116 (43.8)350 (18.9)48 (3.0)Exacerbations in the previous year, n (%)0–1 without hospitalization176 (66.4)≥2 or requiring hospitalization89 (33.6)Abbreviations: SD, standard deviation; FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council. Clinical and Functional Characteristics of the Study Population (N = 273) Abbreviations: SD, standard deviation; FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council. Peak Inspiratory Flow Under standard conditions, 96.0% of patients achieved a PIF ≥30 L/min at R4. When the threshold was increased to ≥60 L/min, the proportion decreased to 61.9%, indicating that 38.1% of the cohort had a limited ability to generate higher inspiratory flows (Figure 1). Peak inspiratory flow achieved under standard conditions according to the predefined thresholds. The proportion of COPD patients achieving peak inspiratory flow (PIF) ≥30 L/min and ≥60 L/min under standard inhalation conditions is shown. Measurements were obtained using the In-Check Dial. The threshold of ≥30 L/min represents the minimum inspiratory flow considered sufficient for medium- to high-resistance dry powder inhalers, whereas ≥60 L/min represents the higher inspiratory flow required by some lower-resistance devices. Impact of Incomplete Exhalation Incomplete exhalation had only a modest effect on inspiratory performance. At the higher resistance setting (R4), 94.1% of patients continued to achieve a PIF ≥30 L/min. A greater reduction was observed for the ≥60 L/min threshold, highlighting the importance of correct inhalation technique when considering devices that require higher inspiratory flows (Figure 2). Effect of incomplete exhalation on peak inspiratory flow. Peak inspiratory flow measured after incomplete exhalation (from functional residual capacity) compared with the standard manoeuvre. Results are presented for the predefined inspiratory flow thresholds and according to the simulated inhaler resistance (R2 and R4). Factors Associated with PIF Age was not significantly associated with the ability to achieve PIF ≥60 L/min at R2 (59.8% in patients <65 years vs 62.9% in those ≥65 years; p = 0.614). At R4, severe dyspnea (mMRC 3–4) and severe airflow limitation (FEVL1 <50% predicted) were associated with a lower probability of achieving PIF ≥30 L/min (p <0.001 and p = 0.015, respectively). Detailed results are presented in Table 2. Table 2Bivariate Analysis of the Proportion of Patients Achieving PIF Thresholds According to Clinical Variables (N = 273)VariablePIF ≥30 L/min (R4)* (%)p-valuePIF ≥60 L/min (R2)** (%)p-valueAirflow limitation (FEV1% predicted)FEV1 ≥50%98.80.01561.9†n.d.FEV1 <50%92.2–––Dyspnea (mMRC scale)mMRC 0–1100<0.001–n.d.mMRC 297.2–––mMRC 3–487.3–––Age<65 years1000.61459.80.614≥65 years94.7–62.9–Notes: *Measured using the In-Check Dial at R4 (simulating medium- to high-resistance DPIs). **Measured at R2 (simulating medium-low resistance DPIs). †Overall cohort value; subgroup breakdown not available for this threshold due to limited events.Abbreviations: FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; PIF, peak inspiratory flow; n.d., not determined. Bivariate Analysis of the Proportion of Patients Achieving PIF Thresholds According to Clinical Variables (N = 273) Notes: *Measured using the In-Check Dial at R4 (simulating medium- to high-resistance DPIs). **Measured at R2 (simulating medium-low resistance DPIs). †Overall cohort value; subgroup breakdown not available for this threshold due to limited events. Abbreviations: FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; PIF, peak inspiratory flow; n.d., not determined. Differential Inspiratory Capacity According to Device Resistance (R2 vs R4) The proportion of patients achieving the predefined PIF thresholds differed according to the simulated device resistance (Table 3). At R2 (medium-low resistance), 61.9% of patients achieved the target PIF of ≥60 L/min. At R4 (medium-high resistance), 96% reached the clinically relevant threshold of ≥30 L/min. Following incomplete exhalation, 94.1% of patients still achieved a PIF ≥30 L/min at R4. Table 3Peak Inspiratory Flow (PIF) According to Device Resistance and Inhalation Conditions (N = 273)Resistance (In-Check Dial)PIF ≥30 L/min (%)PIF ≥60 L/min (%)Full exhalationPartial exhalationFull exhalationPartial exhalationR2 (medium-low resistance)98.297.461.958.6R4 (medium-high resistance)96.094.1—*—Notes: *The ≥60 L/min threshold is clinically relevant only for low-resistance devices (R2), whereas ≥30 L/min is considered the appropriate threshold for medium- to high-resistance devices (R4). Peak Inspiratory Flow (PIF) According to Device Resistance and Inhalation Conditions (N = 273) Notes: *The ≥60 L/min threshold is clinically relevant only for low-resistance devices (R2), whereas ≥30 L/min is considered the appropriate threshold for medium- to high-resistance devices (R4). No formal statistical comparison between the R2 and R4 resistance settings was performed because the study was designed to describe the proportion of patients achieving clinically relevant PIF thresholds at each resistance setting rather than to compare resistance settings directly. Patient Perception and Satisfaction Analysis of the recorded reasons for spacer prescription showed that technical considerations predominated over functional ones (Table 4). In 90.8% of cases, spacer prescription was related to difficulties with pMDI use, particularly the need to ensure correct dose delivery (42.0%) and poor hand–breath coordination (37.3%). By contrast, only 9.2% of prescriptions were explicitly attributed to suspected insufficient inspiratory flow. Table 4Main Reasons for Prescribing pMDI with Spacer (N = 273)Type of IndicationSpecific ReasonPatients (%)pMDI-related factors90.8Ensuring correct dose delivery42.0Difficulty coordinating inhalation37.3Poor understanding of inhaler instructions11.5Pulmonary function-related factors26.0Reduced lung capacity16.8Insufficient inspiratory flow9.2Other / Unknown14.2Note: Percentages do not sum to 100% because indications were not mutually exclusive; a single patient could have more than one reason for spacer prescription. Bold values indicate the overall proportion of patients within each indication category. Main Reasons for Prescribing pMDI with Spacer (N = 273) Note: Percentages do not sum to 100% because indications were not mutually exclusive; a single patient could have more than one reason for spacer prescription. Bold values indicate the overall proportion of patients within each indication category. Patient-reported outcomes further indicated that spacer use imposed a substantial practical burden in daily life (Table 5). A total of 71% of patients reported difficulties carrying the spacer outside the home, 50% reported problems related to cleaning the device, and 40% stated that it interfered with their daily activities. Based on the questionnaire item assessing overall satisfaction with spacer use, 75% of patients reported being satisfied or very satisfied. Despite this, there was a clear preference for treatment simplification: 72% believed they could use an inhaler without a spacer, and 74% stated that they would prefer to discontinue spacer use if a more convenient alternative were available. Table 5Patient Perception of Spacer UseDomainSpecific ItemPatients (%)KnowledgeUnaware of the reason for using a spacer60Unaware of alternative inhaler options16SatisfactionSatisfied with overall spacer use (very/quite satisfied)75Barriers and limitationsDifficulty carrying the spacer (portability)71Difficulty maintaining the device clean and usable50Interference with daily activities40Limitations due to device size and weight38PreferenceBelieves they could use another inhaler and would prefer not to use a spacer72Would prefer to discontinue spacer use if a more convenient alternative were available74Notes: Percentages represent the proportion of patients who responded affirmatively to each item in the perception survey. Patient Perception of Spacer Use Notes: Percentages represent the proportion of patients who responded affirmatively to each item in the perception survey. Discussion The present study shows that 96% of COPD patients treated with pMDI+spacer were able to generate sufficient inspiratory flow to effectively activate medium- to high-resistance DPIs. This observation is consistent with previous studies in stable outpatient populations. Janssens et al13 and Ohar et al7 reported success rates above 95% for the 30 L/min threshold, supporting the robustness of this cutoff across different clinical settings. Our cohort, however, represents a distinct population, as it consisted exclusively of patients already receiving treatment with pMDI+spacer, a group often presumed to have greater functional limitations. The high proportion of patients achieving the target PIF challenges this assumption. Although the present study shares a common methodological framework with our previously published USE-DPI asthma cohort,8 the populations and study objectives differ substantially. The previous study included asthma patients, including pediatric subjects, whereas the current analysis focuses on stable COPD patients treated with pMDI plus spacer devices. It also examines the relationship between inspiratory flow, disease severity, spacer prescribing patterns, and patient-reported burden in routine clinical practice. When a more demanding threshold (≥60 L/min) was applied, the proportion of patients achieving the target PIF decreased to 61.9%, indicating that 38.1% of the cohort had a limited ability to generate higher inspiratory flows. This result is in agreement with reports by Ghosh et al,5,6 who described failure rates ranging from 20% to 45%, and with real-world data from Pankovitch et al,14 in which 28% of outpatients had suboptimal PIF. Taken together, these studies indicate that inspiratory capacity in COPD is highly variable and reinforce the value of objective PIF assessment when selecting an inhaler device, as previously proposed by Mahler and Halpin.15 In the bivariate analysis, age was not significantly associated with the ability to achieve a PIF ≥60 L/min (p = 0.614), whereas severe dyspnea (mMRC grade 3–4) and severe airflow limitation (FEV1 <50% predicted) were associated with lower inspiratory flow (Table 2). These results differ from those of Malmberg et al,16 who identified age and sex as major determinants of inspiratory flow. One possible explanation is that our cohort consisted of clinically stable outpatients without recent exacerbations, in whom inspiratory functional reserve may have been relatively preserved. Conversely, our observations are consistent with those of Janssens et al,13 who identified hyperinflation and the severity of airflow limitation, rather than age, as the principal determinants of PIF in advanced COPD. Another notable aspect of this study is the evaluation of inspiratory flow following incomplete exhalation. Even under these suboptimal conditions, 94.1% of patients achieved a PIF ≥30 L/min (Figure 2 and Table 3), suggesting that many patients retain sufficient inspiratory reserve to tolerate moderate technique errors without compromising device activation. This observation is consistent with previous studies examining the effects of exhalation and lung emptying before inhalation on DPI performance.l11,12 The greater reduction observed at the ≥60 L/min threshold nevertheless emphasizes the importance of correct inhalation technique, particularly when devices requiring higher inspiratory flows are prescribed. The relationship between device resistance and inspiratory flow also deserves consideration. Although patients with COPD are often assumed to benefit from low-resistance DPIs, our results suggest that medium- to high-resistance devices may be appropriate for many patients. While 38.1% of patients failed to achieve ≥60 L/min at R2 (medium-low resistance), 96% reached ≥30 L/min at R4 (medium-high resistance) (Table 3). This apparent paradox is explained by the design of higher-resistance DPIs, which generate sufficient turbulent energy for powder de-aggregation at lower inspiratory flows.10 Rather than considering inspiratory flow alone, these data underline the importance of matching the patient’s inspiratory capacity to the resistance characteristics of the selected device. Comparison of functional capacity with prescribing patterns revealed a notable discrepancy. Although most patients demonstrated adequate inspiratory capacity for medium- to high-resistance DPIs (Table 3), suspected insufficient inspiratory flow was documented as the reason for spacer prescription in only 9.2% of cases (Table 4). This observation suggests that spacer prescribing is frequently influenced by anticipated technical difficulties or established prescribing habits rather than objective physiological assessment. Incorporating routine PIF measurement into clinical practice could help align inhaler selection with patients’ functional capacity and identify opportunities to simplify treatment when appropriate. Patient-reported outcomes provide additional insight into the practical consequences of spacer use. Despite demonstrating adequate inspiratory capacity, 72% of patients believed they could use an inhaler without a spacer, and 74% stated that they would prefer to do so. In addition, 60% were unaware of the reason why the spacer had originally been prescribed (Table 5), suggesting room for improvement in patient education and clinician–patient communication. Although most patients reported being satisfied with spacer use, responses to the remaining questionnaire items identified several practical drawbacks, including limited portability, cleaning requirements, and interference with daily activities. Similar observations have been reported in previous reviews, which describe inhaler selection as being influenced not only by physiological considerations but also by practical and prescriber-related factors.17 Together, these findings support a more individualized approach to inhaler selection that incorporates both objective physiological assessment and patient preferences whenever clinically appropriate. Limitations This study has several limitations that should be considered when interpreting the results. First, its cross-sectional design does not allow assessment of the long-term clinical impact of inhaler switching based on PIF, including outcomes such as exacerbation rates, treatment adherence, or symptom control. Prospective studies are needed to determine whether PIF-guided inhaler selection translates into improved clinical outcomes and to further compare COPD and asthma populations within the USE-DPI research framework. Second, PIF was measured using the In-Check Dial, which simulates device resistance with well-established validity but does not fully reproduce the inspiratory flow characteristics of every commercially available DPI. Consequently, the measured PIF values cannot be assumed to be directly interchangeable across all inhaler devices. Third, PIF was assessed during a single study visit under stable clinical conditions. Inspiratory flow may vary over time and according to disease status, particularly during exacerbations or episodes of clinical deterioration. Therefore, PIF assessment should be interpreted as one component of the overall clinical evaluation rather than the sole determinant of inhaler selection. Fourth, the high proportion of patients achieving the ≥30 L/min threshold precluded reliable multivariable modelling for this outcome because of the limited number of events, restricting further analysis of factors associated with this cutoff. Fifth, the questionnaires used to assess patient knowledge, satisfaction, and perceived barriers were specifically developed for this study and had not undergone external validation. Although they are provided as Supplementary Material to improve transparency and reproducibility, the results derived from these instruments should be interpreted with appropriate caution. Finally, the study population was predominantly recruited from specialized pulmonology clinics, which may limit the generalizability of the findings to COPD patients managed primarily in primary care settings, where disease severity and functional characteristics may differ. In conclusion, most COPD patients treated with pMDI+spacer appear to have sufficient inspiratory capacity to use medium- to high-resistance DPIs. The ability to generate the required inspiratory flow was more closely associated with disease severity—particularly dyspnea and airflow limitation—than with age. These findings support the use of objective PIF assessment as part of an individualized approach to inhaler selection and treatment reassessment. Nevertheless, inhaler choice should always integrate inspiratory capacity with other relevant clinical factors, inhaler technique, patient preferences, and the characteristics of the available devices. Funding Statement This study was supported by an unrestricted educational grant from Orion Pharma. The sponsor had no role in the study design, data collection, analysis, interpretation of the results, or in the decision to submit the manuscript for publication. All authors maintained full independence in conducting the research and preparing the manuscript. Data Sharing Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure L Bravo Quiroga reports consulting fees and payment or honoraria for lectures and presentations from AstraZeneca, CSL Behring, Chiesi, GSK, and Zambon; support for the manuscript from Orion Company, during the conduct of the study; meeting/travel support from Meetings Separ, outside the submitted work. JM González-Moro has received honoraria for training and consultancy from AstraZeneca, GSK, MSD, Orion, and Sanofi-Regeneron, and support for professional activities from Vitalaire; meeting/travel support from GSK, AstraZeneca, Orion Pharma, Menarini, outside the submitted work. FJ Álvarez-Gutiérrez has received honoraria for training and consultancy from AstraZeneca, GSK, Orion, and Sanofi-Regeneron, and support for professional activities from AstraZeneca, Sanofi-Regeneron, Chiesi, Gebro, and Menarini. K Baynova reports data safety/advisory board participation from CSL, Otsuka, Biocryst, outside the submitted work. M de la Poza reports consulting fees and payment or honoraria for lectures and presentations from AstraZeneca, GSK, Boehringer Ingelheim, Orion, Pfizer, Teva, and Almirall; data safety/advisory board participation from Astra Zeneca; leadership or fiduciary roles from Sociedad Española de medicina general y de familia; equipment/materials/services from Astra Zeneca, Orion, Boehringer Ingelheim, Pfizer and other, outside the submitted work. JL Izquierdo reports grants or contracts from GSK and AstraZeneca; consulting fees and payment or honoraria for lectures and presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Grifols, Menarini, Novartis, Orion, Pfizer, Sandoz, Teva, and Zambon. The authors declare that the funding received did not influence the study design, results, or conclusions. References Associated Data Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request.